Navigation Links
Stroke study reveals key target for improving treatment and suggests that Gleevec may help
Date:6/22/2008

ANN ARBOR, Mich. For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke. But its promise is blemished by two facts: tPA can cause dangerous bleeding in the brain, and its brain-saving power fades fast after the third hour of a stroke.

Now, a new paper published online in Nature Medicine reveals why tPA has these limitations. It also gives tantalizing evidence about how those problems might be overcome, if a stroke victim first takes a drug currently used to treat leukemia.

The researchers, from the University of Michigan and the Ludwig Institute at the Karolinska Institutet in Stockholm, Sweden, emphasize that it's still too early to apply their findings made in mice to the treatment of stroke victims everywhere.

But the Karolinska Institutet team will soon begin a clinical trial to test the theory in humans, using the leukemia drug known as imatinib (Gleevec). In mice, that drug greatly reduced bleeding, even if tPA wasn't given until five hours after a stroke began.

The new paper details a series of molecular and cellular experiments conducted by the two teams, which began collaborating after hearing of each other's work.

They report that tPA apparently causes its risk of bleeding, and leakage of fluid within the brain, by accident. The culprit: tPA's tendency to act upon a protein called PDGF-CC, and the PDGF-alpha receptor that it binds to. This interaction causes the usually impervious "blood-brain barrier" to become porous, leading to leakage. Gleevec inhibits the PDGF-alpha receptor, apparently counteracting tPA's effect.

This unwanted effect on the blood-brain barrier appears to be unrelated to tPA's main job, which is to break down clots that have lodged in the brain's blood vessels, cutting off blood supply to the area and starving brain tissue until it begins to die.

Such clots cause 8
'/>"/>

Contact: Kara Gavin
kegavin@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

0

GOOD

Page: 1 2 3 4

Related biology news :

1. Blood pressure drug telmisartan shows powerful activity against stroke
2. Stroke victims may benefit from stem cell transplants
3. Blueberry and green tea containing supplement protects against stroke damage
4. Scientists ask whether microscaffolding can help stem cells rebuild brain after stroke damage
5. Can micro-scaffolding help stem cells rebuild the brain after stroke?
6. Tracking stroke
7. New 3-D ultrasound could improve stroke diagnosis, care
8. Study finds possible connection between marijuana abuse and stroke or heart attacks
9. Even low levels of air pollution may pose stroke risk
10. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
11. A study by the MUHC and McGill University opens a new door to understanding cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stroke study reveals key target for improving treatment and suggests that Gleevec may help
(Date:6/19/2013)... Medicines Agency (EMA) approved the modified adeno-associated virus ... for clinical use in the Western world. uniQure, ... for the treatment of a rare inherited metabolic ... approximately one or two out of one million ... the pancreas. Afflicted individuals carry a defect in ...
(Date:6/18/2013)... from the United Kingdom, the Energy Department,s National ... Kentucky have recently published a paper describing a ... Limnoria quadripunctata , commonly known as the ... they exhibit a relatively unique ability to produce ... to break down the biomass they eat. New ...
(Date:6/18/2013)... of Molecular Biology, has been honored as a ... Torrent is being recognized for his outstanding research, ... antimicrobial regions in proteins. Luis Rivas, Centro de ... algorithm to interrogate full genomes in order to ... results." , Torrent obtained his Ph.D. from ...
Breaking Biology News(10 mins):No danger of cancer through gene therapy virus 2Novel enzyme from tiny gribble could prove a boon for biofuels research 2The American Society for Microbiology honors Marc Torrent 2
... an inherited genetic basis for racial and ethnic disparities ... increased risk of relapse in young leukemia patients. The ... Research Hospital and the Children,s Oncology Group (COG). ... new marker of poor treatment outcome, researchers reported evidence ...
... N.C. Everyone knows chocolate is critical to a happy Valentine,s ... a heart happy the rest of the year. It,s a ... DOT1L enzyme, you could be at risk for some types of ... the University of North Carolina at Chapel Hill School of Medicine ...
... Reserve University have developed a little bomb that promises a ... an anti-cancer drug loosely attached to gold nanoparticles starts accumulating ... activated for an effective treatment within two hours. The same ... the tumor from the surface a far less effective ...
Cached Biology News:Native American ancestry linked to greater risk of relapse in young leukemia patients 2Native American ancestry linked to greater risk of relapse in young leukemia patients 3Just in time for Valentine's Day: UNC researchers identify a gene critical for heart function 2A loose grip provides better chemotherapy 2
(Date:6/19/2013)... 19, 2013   NineSigma , Inc., of ... following its launch, NineSights.com is now the ... for the worldwide community of innovators. From ... sustainability experts, NineSights stands out for its large community ... and technical disciplines, all vetted by NineSigma. The community ...
(Date:6/19/2013)... Atlanta (PRWEB) June 19, 2013 Today ... urged young people to become leaders in the greatest ... 9 billion people in 2050. Borel spoke at ... Conference in Atlanta, about urgent need for students ... that are local, science-based, sustainable and reached in collaboration ...
(Date:6/19/2013)... June 19, 2013 ... presents Innovative Drug Delivery Systems: ... Licensing Opportunities for Generic Pharmaceutical ... There are more than ... drugs approved all over the ...
(Date:6/19/2013)... India’s vast and growing population means ... up to a billion dollars per year by ... taking serious action to better regulate and oversee ... will examine:, ,     Recent changes in ... long term impacts ,     Foreseeable opportunities ...
Breaking Biology Technology:NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3DuPont Leader Calls for New Generation of Food Visionaries to Fight Hunger 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3
... revolutionary surgical instrument system that is smaller in diameter than a ... implantation of the VerteLoc™ Minimally Invasive Spine Stabilization System and will ... Arizona starting on March 12, 2009. , ... Winston-Salem, ...
... In ClearTrial v2.7, the newest version of ... Portfolio Planning capability which enables clinical development ... into portfolio-level forecasts in minutes. The ... monthly resource demand, and timelines across a ...
... Enobia Pharma, an emerging Canadian biotech company ... disorders, today announced completion of target enrollment in ... a severe form of hypophosphatasia. Enobia is ... the treatment of this rare and often crippling ...
Cached Biology Technology:VGI Announces the Launch of DISMISS Instruments for the VerteLoc™ Minimally Invasive Spine Stabilization System 2ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 2ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 3ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 4Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia 2Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia 3
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
WTAP Antibody...
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: